CD38 high /HLA‐DR + CD8 + T lymphocytes display pathogen‐specific expansion regardless of hemophagocytic lymphohistiocytosis
European Journal of Immunology · 2024
DOI: 10.1002/eji.202451140 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Immunology, 2024. Verfasst von Lorenzo Lodi und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Sciences, University of Florence, Florence, Italy. Hauptthemen laut MEDLINE: Lymphohistiocytosis, Hemophagocytic, ADP-ribosyl Cyclase 1, CD8-Positive T-Lymphocytes, HLA-DR Antigens. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The characteristic expansion of T CD38 high /HLA‐DR + CD8 + lymphocytes observed in hemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS) proved able to distinguish HLH/MAS from sepsis and systemic juvenile idiopathic arthritis. However, the performance of this marker in differentiating HLH/MAS from other pediatric febrile conditions with similar clinical onset and yet entirely different treatments remains unexplored. CD38 high /HLA‐DR + CD8 + frequencies measured in the peripheral fresh blood of pediatric patients attended for suspicion of HLH/MAS were retrospectively recorded and clinical characteristics were retrieved. CD38 high /HLA‐DR + CD8 + frequencies in HLH/MAS patients (15 patients; median: 22.0%, IQR: 11.0–49.0%) were compared with those who presented febrile conditions other‐than‐HLH (28 patients; median: 13.0%, IQR: 3.9–28.7%; p = 0.24). HLH and non‐HLH patients were subsequently regrouped based on the presence of an identified infection (22 patients; median: 27.0%, IQR: 15.2‐72.1%) and compared with those without infections (21 patients; median: 7.6%, IQR: 3.7–24.3%; p = 0.0035). CD38 high /HLA‐DR + CD8 + percentages were significantly higher only in the infection group compared with the noninfection one, with a patent pathogen‐specific expansion in Epstein–Barr virus primoinfection and visceral leishmaniasis regardless of the presence of HLH. CD38 high /HLA‐DR + CD8 + frequencies do not appear as an HLH‐specific marker as they naturally expand in other clinical situations that are common in childhood and may mimic HLH initial presentation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Health Sciences, University of Florence, Florence, Italy.
- Immunology Unit, Meyer Children's Hospital IRCCS, Florence, Italy.
- Rheumatology Unit, Meyer Children's Hospital IRCCS, Florence, Italy.
- Pediatric Hematology-Oncology Department, Meyer Children's Hospital IRCCS, Florence, Italy.
- Hepatology Unit, Meyer Children's Hospital IRCCS, Florence, Italy.
- Department NEUROFARBA, University of Florence, Florence, Italy.
ORCID-Profile: Maria Vincenza Mastrolia
Zitieren
APA
Lodi, L., Sarli, W. M., Ricci, S., Pisano, L., Boscia, S., Mastrolia, M. V., Malinconi, S., Fusco, E., Sieni, E., Indolfi, G., Simonini, G., Galli, L., & Azzari, C. (2024). CD38 high /HLA‐DR + CD8 + T lymphocytes display pathogen‐specific expansion regardless of hemophagocytic lymphohistiocytosis. European Journal of Immunology. https://doi.org/10.1002/eji.202451140
Vancouver
Lodi L, Sarli WM, Ricci S, Pisano L, Boscia S, Mastrolia MV, et al. CD38 high /HLA‐DR + CD8 + T lymphocytes display pathogen‐specific expansion regardless of hemophagocytic lymphohistiocytosis. European Journal of Immunology. 2024. doi:10.1002/eji.202451140
BibTeX
@article{Lodi2024,
author = {Lodi, Lorenzo and Sarli, Walter Maria and Ricci, Silvia and Pisano, Laura and Boscia, Silvia and Mastrolia, Maria Vincenza and Malinconi, Sara and Fusco, Eleonora and Sieni, Elena and Indolfi, Giuseppe and Simonini, Gabriele and Galli, Luisa and Azzari, Chiara},
title = {CD38 high /HLA‐DR + CD8 + T lymphocytes display pathogen‐specific expansion regardless of hemophagocytic lymphohistiocytosis},
journal = {European Journal of Immunology},
year = {2024},
doi = {10.1002/eji.202451140}
}
EUVIMED